COMMUNIQUÉS West-GlobeNewswire

Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
11/03/2026
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone [...]
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea
11/03/2026
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure- [...]
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
11/03/2026
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan [...]
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
11/03/2026
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas [...]
Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth
11/03/2026
Fully Funded Growth Strategy Supports Aircraft Fleet Expansion Providing Capacity to Service Current Demand in New Regions FORT MILL, S.C., March 11, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: [...]
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
11/03/2026
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior [...]
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a [...]
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
11/03/2026
ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” [...]
Lighter. Cheaper. Funner. Pub Light Is Here.
11/03/2026
Pub Beer introduces a 99‑calorie American‑style light lager at 4% ABV BEND, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Pub Beer , the Cheap Fun beer brand by Tilray Brands, Inc . (Nasdaq: TLRY; TSX: TLRY), today announced [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
Encouraging Sports Enthusiasts to Move Better Through Smarter Recovery New York, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign "Train Hard, [...]
Trading by management and close relations of management
11/03/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
11/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2
11/03/2026
Le traitement par niraparib et acétate d’abiratérone démontre un retard cliniquement significatif dans la progression de la maladie, réduisant de près de moitié le risque de progression ou de décès, avec une tendance [...]
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
11/03/2026
Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) , a molecular genetics diagnostic company [...]
Community Care Cooperative (C3) Earns $10.2 Million in Shared Savings Through Medicare Shared Savings Program (MSSP) Track A for Performance Year 2024
11/03/2026
BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Community Care Cooperative (C3), the largest and most successful non-profit, FQHC-governed ACO in the country, announced today that it achieved $10.2 million in shared savings [...]
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
11/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Throughout February this year, smart wellness innovator UREVO launched its new campaign, " Train Hard, Recover Smart ," encouraging sports enthusiasts worldwide to take a [...]
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
11/03/2026
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or [...]
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]

Pages